Clinical Trials Browser

Approved for marketing × daratumumab × Clear all

NCT02477891 2019-01-15

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Approved for marketing

Multiple Myeloma